In the ever-evolving world of healthcare, the role of antithrombin in medical practice continues to expand, solidifying its position as a critical player in preventing and controlling unwanted blood clotting. This comprehensive report unlocks insights into the flourishing antithrombin market that is garnering increased attention due to its critical role in managing coagulation disorders, open heart surgeries, and rabid therapeutic advancements. The escalating occurrence of heart diseases, the prevalence of chronic conditions and the surge in need for surgical procedures are all factors propelling the demand for antithrombin.
Furthermore, the report covers the landscape of the antithrombin market, including various sectorial trends, innovative clinical trials, and region-specific performance. Get a comprehensive understanding of market influencers and important clinical developments. Gain insights into how these variables are contributing to the increasing demand for antithrombin. Arm your business strategy with unmatched knowledge in this essential aspect of healthcare with this carefully compiled, insightful antithrombin market research report.
The impact of COVID-19 on the antithrombin market was substantial in the initial phase owing to factors such as the closure of manufacturing facilities and research and development activities. However, the increasing use of antithrombin in COVID-19 patients has accelerated the demand for these products within the market. For instance, as per the report published by Acta Haematologica in December 2022, in severe COVID-19 patients, low antithrombin activity is linked to mortality as well as pro-inflammatory and prolonged hypercoagulable states. Antithrombin is a promising therapeutic target for future research in COVID-19 infection because of its anti-thromboinflammatory characteristics and is expected to attain growth in the market over the coming years.
The factors that drive the market include increasing coagulation diseases and open heart surgeries and increasing usage of diagnostic kits using antithrombin. Antithrombin is crucial since it stops excessive blood clotting. Due to the rise in chronic conditions like heart disease and kidney disease, the usage of antithrombin in surgical procedures has increased. Antithrombin is required during surgery to stop blood clots from forming. Hence, an increase in surgical procedures due to chronic diseases and a rise in antithrombin insufficiency have led to an increase in antithrombin demand, which will help the market grow.
For instance, according to the British Heart Foundation's 2022 report, in the United Kingdom, 7.6 million people suffer from heart and circulation conditions. Furthermore, these figures may continue to climb as a result of underlying conditions that affect the heart and circulatory system, an aging and growing population, as well as other factors. Hence, the high burden of heart and circulatory diseases raises the demand for surgical procedures, thereby increasing the usage of antithrombin and is expected to drive the market over the study period.
Furthermore, in December 2022, Octapharma stated that the ATN-06 study is investigating the use of Atenativ, a Plasma-Derived Antithrombin Concentrate, in people with congenital antithrombin deficiency undergoing surgery or childbirth. Thus with new studies on antithrombin deficiency treatments, the demand for antithrombin drugs increases, which is expected to drive the market over the forecast period.
However, the alternative supplements and the high cost of antithrombin therapy are expected to hinder the growth of the market over the forecast period.
Antithrombin Market Trends
Therapeutics Segment is Expected to Hold a Large Market Share Over the Forecast PeriodAntithrombin can be used as a treatment option in conditions like cardiac surgeries and in genetic conditions like hereditary antithrombin deficiency. Hereditary antithrombin deficiency, also known as antithrombin III deficiency or AT III deficiency, is a disorder in which individuals are at increased risk for developing blood clots and causing various heart diseases. Approximately 50% of individuals with Hereditary antithrombin deficiency will develop one or more clots in their lifetime, usually after adolescence which need proper treatment with antithrombin. Hence, the segment is expected to drive the market over the study period.
Furthermore, new research studies on the treatment of various antithrombin deficiencies can expand the applications of various drugs and help the market to grow over the study period. For instance, the study report published by the journal Thrombosis Update in December 2021 recommended using low molecular weight heparin (LMWH) during pregnancy with regular anti-Xa monitoring to ensure that women receive adequate antithrombotic therapy. Due to the effectiveness of LMWH activating antithrombin, substantial doses of LMWH are typically needed in people with antithrombin deficiency. Hence, with new studies, the usage of antithrombin drugs increases, which is expected to drive the market over the study period.
Asia-Pacific is Expected to be the Fastest Growing Region Over the Forecast PeriodThe Asia-Pacific region is expected to show high growth due to developing nations such as India and China that are embracing new treatment procedures and techniques to combat various diseases. The increase in non-refundable incomes in developing countries and their increasing capability to invest more money in advanced healthcare creates more opportunities for the market in the Asia Pacific. Furthermore, the rising burden of old age, along with increasing thrombosis diseases and new studies for antithrombin deficiency in the region, is expected to drive the market over the forecast period.
The population of the elderly in India has been increasing, which is a major factor driving the market in the region. For instance, as per the study by NSO, in 2021, the proportion of the elderly population in India was projected to be 10.1% in 2021 and 13.1% in 2031. As the elderly population increases, the risk of thrombosis is high and is expected to have an increased demand for antithrombin treatment and drive the market.
Furthermore, the new studies on antithrombin deficiency in the region are expected to increase the products of antithrombin and drive the market. For instance, as per the Frontiers in Neurology in June 2022, antithrombin deficiency is caused by various reasons, one of which is by inherited variants in the SERPINC1 gene. Hence, the SERPINC1 gene test is useful in determining the cause of antithrombin deficiency-related arterial thrombosis, especially ischemic stroke. Thus, the new studies in antithrombin deficiency help to increase the usage of specific diagnostic products and drive the market over the forecast period.
Antithrombin Industry OverviewThe antithrombin market is moderately competitive and consists of several major players. Some of the major market players are CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, and Lee Biosolutions Inc.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Coagulation Diseases and Open Heart Surgeries
4.2.2 Increasing Usage of Diagnostic Kits Using Antithrombin
4.3 Market Restraints
4.3.1 Adoption of Alternative Supplements due to High Cost of Antithrombin Therapy
4.4 Porter Five Forces
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.2 By Source
5.2.2 Recombinant Goat Milk
5.3 By Type
5.3.3 Thrombolytic Drugs
5.4 By Route of Administration
5.5.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.5.4 Middle East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East and Africa
5.5.5 South America
188.8.131.52 Rest of South America
6.1.2 Grifols, S.A
6.1.3 Takeda Pharmaceutical Company Limited
6.1.4 Octapharma AG
6.1.5 LFB USA
6.1.6 Endpoint Health, Inc.
6.1.7 Siemens Healthcare GmbH
6.1.8 Thermo Fisher Scientific
6.1.9 Medix Biochemica (Lee Biosolutions)
A selection of companies mentioned in this report includes:
- Grifols, S.A
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- LFB USA
- Endpoint Health, Inc.
- Siemens Healthcare GmbH
- Thermo Fisher Scientific
- Medix Biochemica (Lee Biosolutions)